Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression

References

• Monz D, Munnia A, Comtesse N, et al. Novel Tankyrase-related Gene Detected with Meningioma-specific Sera. Clin Cancer Res 2001;7:113–19.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO classification of tumors of the central nervous system. 4th edition. Lyon: IARC Press, 2007.
   Google Scholar
• Kolles H, Niedermayer I, Schmitt CH, et al. Triple approach for diagnosis and grading of meningiomas: histology, morphometry of Ki-67/Feulgen stainings and cytogenetics. Acta Neurochir 1995;137:174–81.
   PubMed Web of Science ®Google Scholar
• Mirimanoff RO, Dosoretz DE, Linggood RM, et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985;62:18–24.
   PubMed Web of Science ®Google Scholar
• Korshunov AG, Shishkina LV, Golanov AV. Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value. Arkh Patol 2002;64(1):29–33.
   PubMedGoogle Scholar
• Takei H, Buckleair LW, Powell SZ. Immunohistochemical expression of apoptosis regulating proteins and sex hormone receptors in meningiomas. Neuropathology 2008;28:62–8.
   PubMed Web of Science ®Google Scholar
• Konstantinidou AE, Korkolopoulou P, Mahera H, et al. Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 2003;43:280–90.
   PubMed Web of Science ®Google Scholar
• Karamitopoulou E, Perentes E, Tolnay M, Probst A. prognostic significance of MIB-I, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 1998;29:140–5.
   PubMed Web of Science ®Google Scholar
• Matsuno A, Fujimaki T, Saaki T, et al. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol 1996;91:504–10.
   PubMed Web of Science ®Google Scholar
• Abramovich CM, Prayson RA. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum Pathol 1998;29:1420–7.
   PubMed Web of Science ®Google Scholar
• Amatya VJ, Takeshima Y, Sugiyama K, et al. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol 2001;32(9):970–5.
   PubMed Web of Science ®Google Scholar
• Wahab M, Al-Azzawi F. Meningioma and hormonal influences. Climacteric 2003;6(4):285–92.
   PubMed Web of Science ®Google Scholar
• Benzel EC, Gelder FB. Correlation between sex hormone binding and peritumoral edema in intracranial meningiomas. Neurosurgery 1988;23(2):169–74.
   PubMed Web of Science ®Google Scholar
• Pravdenkova S, Al-Mefty O, Sawyer J, Husain M. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg 2006;105(2):163–73.
   PubMed Web of Science ®Google Scholar
• Blankenstein MA, Koehorst SG, van der Kallen CJ, et al. Oestrogen receptor independent expression of progestin receptors in human meningioma – a review. J Steroid Biochem Mol Biol 1995;53:361–5.
   PubMed Web of Science ®Google Scholar
• Konstantinidou A, Korkolopoulou P, Patsouris E, et al. Apoptosis detected with monoclonal antibody to single-stranded DNA is a predictor of recurrence in intracranial meningiomas. J Neurooncol 2001;55:1–9.
   PubMed Web of Science ®Google Scholar
• Verheijen FM, Donker GH, SalesViera C, et al. Progesterone receptor, bcl-2 and Bax expression in meningiomas. J Neurooncol 2002;56: 35–41.
   PubMed Web of Science ®Google Scholar
• Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MW, Thijssen JH. Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids 2000;65(10–11):795–800.
   PubMed Web of Science ®Google Scholar
• Miyagami M, Kanou T, Nakamura S. P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas. No To Shinkei 1996;48(8):719–25.
   PubMedGoogle Scholar
• Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberio N, Albanese V. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Pathol Res Pract 2000;196(7):483–8.
   PubMed Web of Science ®Google Scholar
• Loussouarn D, Brunon J, Avet-Loiseau H, Campone M, Mosnier JF. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. Hum Pathol 2006;37:415–21.
   PubMed Web of Science ®Google Scholar
• Maiuri F, De Caro Mdel B, Esposito F, et al. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol 2007;82(1):63–8.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Ketter R, Henn W, Zang KD, Steudel WI, Feiden W. Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters. Virchows Arch 2006;449(5):529–38.
   PubMed Web of Science ®Google Scholar
• Salmon I, Kiss R, Levivier M, et al. Characterization of nuclear DNA content, proliferation index, and nuclear size in a series of 181 meningiomas, including benign primary, recurrent, and malignant tumors. Am J Surg Pathol 1993;17:239–47.
   PubMed Web of Science ®Google Scholar
• Jääskeläinen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. Surg Neurol 1986;26(5):461–9.
   PubMedGoogle Scholar
• Schiffer D, Ghimenti C, Fiano V. Absence of histological signs of tumor progression in recurrences of completely resected meningiomas. J Neurooncol 2005;73(2): 125–30.
   PubMed Web of Science ®Google Scholar
• Terzi A, Saglam EA, Barak A, Soylemezoglu F. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol Res Pract 2008;204(5):305–14.
   PubMed Web of Science ®Google Scholar
• Hakin-Smith V, Battersby RD, Maltby EL, Timperley WR, Royds JA. Elevated p53 expression in benign meningiomas protects against recurrence and may be indicative of senescence. Neuropathol Appl Neurobiol 2001;27(1):40–9.
   PubMed Web of Science ®Google Scholar
• Kamei Y, Watanabe M, Nakayama T, Kanamaru K, WagaS, Shiraishi T. Prognostic significance of p53 and p21WAF1/CIP1 immunoreactivity and tumor micronecrosis for recurrence of meningiomas. J Neurooncol 2000;46(3):205–13.
   PubMed Web of Science ®Google Scholar